Oral administration of type II collagen suppresses pro-inflammatory mediator production by synoviocytes in rats with adjuvant arthritis
Open Access
- 29 May 2003
- journal article
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 132 (3) , 416-423
- https://doi.org/10.1046/j.1365-2249.2003.02167.x
Abstract
The objective of this study was to investigate the effect of the oral administration of type II collagen (CII) on pro‐inflammatory mediator production by synoviocytes in rats with adjuvant arthritis (AA). Sprague‐Dawley rats were fed with bovine CII either before immunization with Complete Freund's adjuvant (CFA) or after initiation of arthritis. Hind paw secondary swelling was measured and synoviocytes were harvested. Sera from portal vein of oral tolerized rats were collected and in vitro synoviocytes culture or synoviocytes‐Peyer's Patches (PP) cells coculture system were developed. Interleukin (IL)‐1 activity was measured by a mouse thymocyte activation assayed by MTT dye reduction and tumour necrosis factor (TNF) activity was measured by an L929 cytotoxicity bioassay. Nitric oxide (NO) and malondialdehyde (MDA) levels were measured by biochemical methods. We found that feeding with CII (5, 50 and 500 µg/kg) for 7 days before immunization significantly suppressed hind paw secondary swelling measured at day 16, 20, 24 and 28 (all P < 0·01) and pro‐inflammatory mediator (IL‐1, TNF, NO and MDA) production by synoviocytes (all P < 0·01) in rats with AA. Feeding with CII (5, 50 and 500 µg/kg) for 7 days after initiation of arthritis had a similar effect. CII (1, 10, 100 µg/ml) had no effect on IL‐1 and TNF production by synoviocytes in vitro, but CII 10 µg/ml suppressed IL‐1 and TNF production by synoviocytes‐PP cells coculture system (P < 0·01), which was antagonized by anti‐TGF‐β antibody (10 µg/ml) (P < 0·01). Portal serum (1 : 10) from oral tolerized rats suppressed IL‐1 and TNF production by synoviocytes (P < 0·01), which was also antagonized by anti‐TGF‐β antibody (10 µg/ml) (P < 0·01). We conclude that oral administration of CII had prophylactic and therapeutic effects on AA and over‐production of IL‐1, TNF, NO and MDA by synoviocytes was suppressed. Bystander active suppression may be the main mechanism of oral CII in the suppression of synoviocyte function.Keywords
This publication has 45 references indexed in Scilit:
- T Cell Lines Generated with Type II Collagen Proliferate in an Autologous Mixed Lymphocyte ResponseJournal of Autoimmunity, 2001
- Control of rheumatoid arthritis by oral toleranceArthritis & Rheumatism, 2001
- Treatment of Autoimmune Disease by Oral Tolerance to AutoantigensClinical Immunology and Immunopathology, 1996
- Oral type II collagen treatment in early rheumatoid arthritis. A double‐blind, placebo‐controlled, randomized trialArthritis & Rheumatism, 1996
- Suppression of antigen‐induced arthritis in lewis rats by oral administration of type ii collagenArthritis & Rheumatism, 1995
- Oral Tolerance to Myelin Basic Protein Induces Regulatory TGF-β-Secreting T Cells in Peyer's Patches of SJL MiceCellular Immunology, 1994
- Suppression of Collagen Induced Arthritis by Oral Administration of Type II Collagen: Changes in Immune and Arthritic Responses Mediated by Active Peripheral SuppressionAutoimmunity, 1993
- Increased Urine Interleukin-1 Levels in AgingGerontology, 1993
- Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor beta, interleukin 4, and prostaglandin E expression in the brain.The Journal of Experimental Medicine, 1992
- Tumour necrosis factor in synovial exudates.Annals of the Rheumatic Diseases, 1988